



31 July 2008

Securities and Exchange Commission  
Judiciary Plaza,  
450 Fifth Street,  
Washington DC 20549

SEC  
Mail Processing  
Section

AUG 1 12 2008

Washington, DC  
101

PROCESSED  
AUG 20 2008  
THOMSON REUTERS

**SUPPL**

**Re: Bionomics Limited - File number 82-34682**

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682..

Yours sincerely



Stephen Birrell  
CFO & Company Secretary



# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000 Amended 30/9/2001

Name of entity

**BIONOMICS LIMITED**

ABN

**53 075 582 740**

Quarter ended ("current quarter")

**30-Jun-08****Consolidated statement of cash flows**

	Current quarter \$A'000	Year to date (12 months) \$A'000
<b>Cash flows related to operating activities</b>		
1.1 Receipts from customers <i>(note: Upfront payment (US\$2.0m) from Merck Serono collaboration agreement received in July 2008)</i>	634	2,939
1.2 Payments for		
(a) staff costs	(308)	(1,181)
(b) advertising & marketing	(62)	(312)
(c) research & development (incl. R&D staff costs)	(1,876)	(9,354)
(d) leased assets	(35)	(175)
(e) other working capital	(169)	(973)
1.3 Dividends received	0	0
1.4 Interest and other items of a similar nature received	112	674
1.5 Interest and other costs of finance paid	(15)	(43)
1.6 Income taxes paid	0	0
1.7 Other - Grants	510	2,301
<b>Net operating cash flows</b>	<b>(1,209)</b>	<b>(6,124)</b>
1.8 Net operating cash flows (carried forward)	(1,209)	(6,124)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	0	0
(b) equity investment	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	(233)
(e) other non-current assets	0	0
	Current quarter \$A'000	Year to date (12 months) \$A'000
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investment	0	0

	(c) intellectual property	0	0
	(d) physical non-current assets	0	0
	(e) other non-current assets	0	0
1.11	Loans to other entities	0	0
1.12	Loans repaid by other entities	0	0
1.13	Other	0	0
	<b>Net investing cash flows</b>	0	(233)
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>(1,209)</b>	<b>(6,357)</b>
	<b>Cash flows related to financing activities</b>		
1.15	Proceeds from issues of shares, options, etc.	0	31
1.16	Proceeds from sale of forfeited shares	0	0
1.17	Proceeds from borrowings	0	150
1.18	Repayment of borrowings	(104)	(364)
1.19	Dividends paid	0	0
1.20	Other (capital raising costs)	0	0
	<b>Net financing cash flows</b>	<b>(104)</b>	<b>(183)</b>
	<b>Net increase (decrease) in cash held</b>	<b>(1,312)</b>	<b>(6,540)</b>
1.21	Cash at beginning of quarter/year to date	7,595	12,822
1.22	Exchange rate adjustments to item 1.20		
1.23	<b>Cash at end of quarter (note: Upfront payment (US\$2.0m) from Merck Serono collaboration agreement received in July 2008)</b>	<b>6,282</b>	<b>6,282</b>

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(127)
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Consists of remuneration paid to directors including remuneration paid to the Chief Executive Officer and Managing Director.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

## Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities - Line of Credit	550	550
3.2 Credit standby arrangements	0	0

Explanation necessary for an understanding of financing facilities available

--

## Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,503	1,417
4.2 Deposits at call	4,779	6,178
4.3 Bank overdraft		
4.4 Other (provide details)		
<b>Total: cash at end of quarter (item 1.22) (note: Upfront payment (US\$2.0m) from Merck Serono collaboration agreement received in July 2008)</b>	<b>6,282</b>	<b>7,595</b>

## Acquisitions and disposals of business entities

	Acquisitions \$A'000 (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity		
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

## Compliance statement

This statement has been prepared under accounting policies, which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

Sign here: .....  
(CEO & Managing Director)

31/07/2008

Print name: DEBORAH RATHJEN

### Notes

The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or  
1 notes attached to this report.

The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the  
2 Standard set out below.

- 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
- 9.2 - itemised disclosure relating to acquisitions
- 9.4 - itemised disclosure relating to disposals
- 12.1(a) - policy for classification of cash items
- 12.3 - disclosure of restrictions on use of cash
- 13.1 - comparative information

**Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If  
3. the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

END